Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Barry_Greene
|
| gptkbp:collaboratedWith |
gptkb:Biogen
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
antidepressant medications
|
| gptkbp:focusesOn |
central nervous system disorders
|
| gptkbp:foundedIn |
2010
|
| gptkbp:founder |
gptkb:Jeffrey_Jonas
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sage Therapeutics, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableApproval |
FDA approval for Zulresso in 2019
FDA approval for Zurzuvae in 2023 |
| gptkbp:notableProduct |
gptkb:Zulresso
gptkb:Zurzuvae |
| gptkbp:numberOfEmployees |
over 500
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
neurological disorders
neuropsychiatric disorders |
| gptkbp:stockSymbol |
gptkb:SAGE
|
| gptkbp:tradedOn |
gptkb:NASDAQ:SAGE
|
| gptkbp:website |
https://www.sagerx.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:SAGE
|
| gptkbp:bfsLayer |
6
|